The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605).
T. Hirashima
No relevant relationships to disclose
I. Okamoto
Honoraria - Chugai Pharma; Lilly
H. Yoshioka
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
M. Ando
No relevant relationships to disclose
K. Takeda
No relevant relationships to disclose
T. Seto
No relevant relationships to disclose
N. Yamamoto
No relevant relationships to disclose
H. Saka
No relevant relationships to disclose
K. Asami
No relevant relationships to disclose
S. Kudoh
No relevant relationships to disclose
M. Satouchi
Honoraria - AstraZeneca; Chugai Pharma
N. Ikeda
No relevant relationships to disclose
Y. Iwamoto
No relevant relationships to disclose
T. Sawa
No relevant relationships to disclose
M. Miyazaki
No relevant relationships to disclose
K. Tamura
No relevant relationships to disclose
T. Kurata
Consultant or Advisory Role - Takeda (U)
Honoraria - AstraZeneca; Lilly
M. Fukuoka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo
K. Nakagawa
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical